

Human CD30 Monoclonal Antibody

Catalog No.: YR0005

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Brentuximab is a biosimilar directed against the extracellular domain of CD30. The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30 and delivers the MMAE, which causes apoptosis by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtubule network, thereby preventing tumor growth and proliferation.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Brentuximab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Recommended Isotype Control(s)

Recommended Dilution Buffer

1×PBS pH 7.3

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production


Purified from cell culture supernatant in an animal-free facility

Purification


Protein A or G purification

Storage


Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human TNFRSF8 /CD30 (Research Grade Brentuximab Biosimilar) Monoclonal Antibody to TNFRSF8 /CD30. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human CD30 SPR assay. Determined through SPR assay, the Human Anti-Human CD30 (Research Grade Brentuximab Biosimilar) Monoclonal Antibody is capable of binding to Human CD30 with an affinity constant of 3.719 nM.



Detection of CD30 in K562 cell line by Flow Cytometry. K562 cell line was stained with Human Anti-Human CD30 (Brentuximab Biosimilar) Monoclonal Antibody followed by APC conjugated Anti-Human IgG Secondary Antibody, or unstained cells (open blue histogram).